BRPI0908544A2 - derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes - Google Patents

derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes

Info

Publication number
BRPI0908544A2
BRPI0908544A2 BRPI0908544A BRPI0908544A BRPI0908544A2 BR PI0908544 A2 BRPI0908544 A2 BR PI0908544A2 BR PI0908544 A BRPI0908544 A BR PI0908544A BR PI0908544 A BRPI0908544 A BR PI0908544A BR PI0908544 A2 BRPI0908544 A2 BR PI0908544A2
Authority
BR
Brazil
Prior art keywords
stimulants
diabetes
obtaining
treatment
methods
Prior art date
Application number
BRPI0908544A
Other languages
English (en)
Inventor
Christine Charon
Gérard Botton
Micheline Kergoat
Samer Elbawab
Original Assignee
Merck Patent Ges Mit Berschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Berschränkter Haftung filed Critical Merck Patent Ges Mit Berschränkter Haftung
Publication of BRPI0908544A2 publication Critical patent/BRPI0908544A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0908544A 2008-03-05 2009-01-15 derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes BRPI0908544A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004193 2008-03-05
PCT/EP2009/000213 WO2009109259A1 (en) 2008-03-05 2009-01-15 Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (1)

Publication Number Publication Date
BRPI0908544A2 true BRPI0908544A2 (pt) 2015-09-29

Family

ID=40565210

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908544A BRPI0908544A2 (pt) 2008-03-05 2009-01-15 derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes

Country Status (18)

Country Link
US (2) US8637522B2 (pt)
EP (1) EP2250156B1 (pt)
JP (1) JP5530370B2 (pt)
KR (1) KR101637381B1 (pt)
CN (1) CN101945858B (pt)
AR (1) AR070798A1 (pt)
AU (1) AU2009221328B2 (pt)
BR (1) BRPI0908544A2 (pt)
CA (1) CA2717753C (pt)
DK (1) DK2250156T3 (pt)
EA (1) EA021325B1 (pt)
ES (1) ES2543598T3 (pt)
HU (1) HUE025132T2 (pt)
IL (1) IL207719A (pt)
MX (1) MX2010009575A (pt)
PT (1) PT2250156E (pt)
WO (1) WO2009109259A1 (pt)
ZA (1) ZA201007060B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN102260268B (zh) * 2011-06-19 2013-04-03 漆又毛 苄硫基乙酰胺基乙酰吡嗪三唑衍生物及制备与应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH609989A5 (en) * 1974-06-21 1979-03-30 Hoffmann La Roche Process for the preparation of acyl derivatives
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
WO1998011075A1 (en) 1996-09-16 1998-03-19 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
CA2626220A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
US20090011994A1 (en) * 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods

Also Published As

Publication number Publication date
ZA201007060B (en) 2011-06-29
EP2250156A1 (en) 2010-11-17
IL207719A (en) 2015-05-31
KR20100123900A (ko) 2010-11-25
CN101945858A (zh) 2011-01-12
AU2009221328B2 (en) 2014-02-27
AU2009221328A1 (en) 2009-09-11
HUE025132T2 (en) 2016-01-28
WO2009109259A1 (en) 2009-09-11
CN101945858B (zh) 2014-05-21
JP2011513344A (ja) 2011-04-28
MX2010009575A (es) 2010-09-24
KR101637381B1 (ko) 2016-07-07
JP5530370B2 (ja) 2014-06-25
EA021325B1 (ru) 2015-05-29
US8637522B2 (en) 2014-01-28
IL207719A0 (en) 2010-12-30
CA2717753A1 (en) 2009-09-11
ES2543598T3 (es) 2015-08-20
PT2250156E (pt) 2015-09-09
EP2250156B1 (en) 2015-05-06
US20140100235A1 (en) 2014-04-10
AR070798A1 (es) 2010-05-05
EA201001408A1 (ru) 2011-06-30
US20110015210A1 (en) 2011-01-20
CA2717753C (en) 2016-09-13
DK2250156T3 (en) 2015-08-03
US9102632B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
BRPI0908406A2 (pt) Derivados de quinoxalinona como estimulantes da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para tratamento do diabetes
BRPI0908544A2 (pt) derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes
BRPI0921389A2 (pt) seringa de um só uso, de inutilização automática
CL2015001207A1 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
EP2120959A4 (en) METHOD AND COMPOSITIONS FOR TREATING INSULIN RESISTANCE, DIABETES AND DIABETES-BASED DYSLIPIDEMIA
BRPI0819188A2 (pt) Uso de melanocortinas para tratar sensibilidade à insulina.
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0822380A2 (pt) agulha para coleta de sangue com retrocesso
BRPI0914341A2 (pt) artigos absorventes descartáveis para sexo específico
BRPI0907453A2 (pt) Compostos, uso e preparação dos mesmos
DK1931407T3 (da) Engangssikkerhedssprøjte med tilbagetrækkelig nål
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BRPI0915428A2 (pt) derivados de benzoxazinona atuando como agonistas adrenorreceptor beta2 para o tratamento de distúrbios respiratórios
BRPI0908569A2 (pt) estimuladores de secreção de insulina derivados de piridopirazinonas, métodos para obtê-los e uso dos mesmos para o tratamento de diabetes
BRPI0909096A2 (pt) uso de conjugados de interleicna-1 no tratamento de diabetes
BRPI0910833A2 (pt) Derivado de arilpirazinona como estimuladores da secreção de insulina, métodos para obtenção dos mesmos e uso dos mesmos para o tratamento de diabetes
FR2932481B1 (fr) Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
FI20096410A0 (fi) Mäntypikikoostumus, menetelmä sen valmistamiseksi sekä koostumuksen käyttö
BRPI0918108A2 (pt) composição para tratamento, método de tratamento e uso de uma composição
DK2103321T3 (da) Engangssprøjte
FR2941946B1 (fr) Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2944013B1 (fr) Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time